DescriptorName: Humans. DescriptorName: Non-alcoholic FattyLiverDisease... AbstractText: Nonalcoholic fattyliverdisease (NAFLD) is the most common chronic liver condition worldwide. However, its etiology and fundamental pathophysiology for the disease process are poorly understood. In this study, we thus used bioinformatics to identify candidate genes potentially causative of severe NAFLD AbstractText: Gene expression profile data GSE49541 were downloaded from ...
DescriptorName: Non-alcoholic FattyLiverDisease... conditions and medications taken by diabetic patients with NAFLD and identifying characteristics that may impact liver disease severity or clinical management.Adults with type 2 diabetes have a high prevalence of nonalcoholic fattyliverdisease (NAFLD) and increased risk of developing advanced liver disease.
Endocrine Disorders (2), Neuroscience (1), Cardiovascular Diseases (1) Liver Diseases (6), Diabetes Mellitus, Type 2 (2), Fibrosis (1), more mentions
Abstract: Several prediction models for fattyliverdisease (FLD) are available with limited externally validation and less comprehensive evaluation. The aim was to perform external validation and direct comparison of 4 prediction models (the Fatty Liver Index, the Hepatic Steatosis Index, the ZJU index, and the Framingham Steatosis Index) for FLD both in the overall population and the obese subpopulation ...
Anti-Obesity and Weight Loss (5) Fatty Liver (4), Obesity (1), more mentions
Abstract: Nonalcoholic fattyliverdisease (NAFLD) is a risk factor for coronary artery disease... Based on this classification, all patients were divided into 4 subgroups as grade 0 (no fattyliverdisease), grade 1, grade 2, and grade 3. Hierarchical logistic regression and Cox proportional regression analysis were used to establish the relation between NAFLD grade and outcomes.
AbstractText: Cardiovascular disease (CVD) is the leading cause of death among patients with non-alcoholic fattyliverdisease (NAFLD. Moderate drinking (vs abstinence) is associated with lower risk of CVD in the general population. We assessed whether alcohol use is associated with CVD risk in patients with NAFLD AbstractText: We analyzed data from participants in the Coronary Artery Risk Development ...
Cardiovascular Diseases (4), Endocrine Disorders (2), Anti-Obesity and Weight Loss (1) Cardiovascular Diseases (2), Diabetes Mellitus (2), Fatty Liver (1), more mentions
McMaster PLUS Selected
This article has been identified as especially clinically relevant or newsworthy by at least 3
practicing clinicians and of high scientific quality by expert researchers
as a part of the McMaster PLUS article rating service.
... to compare the influence of sleeve gastrectomy (SG) versus Roux-en-Y gastric bypass (RYGB) on liver function in bariatric patients with non-alcoholic fattyliverdisease (NAFLD) in a randomized clinical trial (NCT01806506) AbstractText: Rapid weight loss and malabsorption after bariatric surgery in patients with NAFLD or steatohepatitis (NASH) may ...
Anti-Obesity and Weight Loss (4), Blood Disorders and Hematology (1), Infectious Diseases (1) Dyslipidemias (1), Fatty Liver (1), Alcoholic Fatty Liver (1), more mentions
AbstractText: To compare the efficacy of ipragliflozin versus pioglitazone in patients with type 2 diabetes complicated by nonalcoholic fattyliverdisease (NAFLD) AbstractText: In this open-label, randomized, active-controlled trial, we randomly assigned 66 patients with type 2 diabetes and NAFLD to receive ipragliflozin 50 mg (n = 32) or ...
Endocrine Disorders (4) Diabetes Mellitus, Type 2 (4), Fatty Liver (2), more mentions
BACKGROUND: Management of metabolic complications of long-term adjuvant endocrine therapy in early breast cancer remained an unmet need. We aimed to compare the effects of tamoxifen (TMX) and aromatase inhibitors (AIs) on the risk of fatty liver in conjunction with longitudinal changes in the serum lipid parameters.
METHODS: Among 1203 subjects who were taking adjuvant TMX or AI (anastrozole or letrozole) without fatty liver at baseline, those taking TMX or AI were 1:1 matched on the propensity score. The primary outcome was newly developed fatty liver detected on annual liver ultrasonography.
RESULTS: Among 328 matched subjects (mean age 53.5 years, body mass index 22.9 kg/m(2)), 62 cases of fatty liver in the TMX group and 41 cases in the AI group were detected in a total of 987.4 person-years. The incidence rate of fatty liver was higher in the TMX group than in the AI group (128.7 versus 81.1 per 1000 person-years, P = 0.021), particularly within the first 2 years of therapy. TMX was associated with an increased 5-year risk of newly developed fatty liver (adjusted hazard ratio 1.61, P = 0.030) compared with AI independent of obesity and cholesterol level. Subjects who developed fatty liver had higher triglycerides (TGs) and lower high-density lipoprotein cholesterol (HDL-C) level at baseline than those without, which was sustained during follow-up despite the serum cholesterol-lowering effect of TMX.
CONCLUSIONS: TMX independently increased the 5-year risk of newly developed fatty liver compared with AI in postmenopausal women with early breast cancer. Our findings suggest the need for considering the risk of fatty liver as a different adverse event profile between AI and TMX, particularly in patients with obesity, high TGs and low HDL-C.
Anti-Obesity and Weight Loss (3), Oncology (3) Fatty Liver (11), Breast Neoplasms (4), Obesity (2), more mentions